ArticleBioengineered2017
The evolution of recombinant thrombolytics: Current status and future directions.
Article in Bioengineered, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 101 citations in OpenAlex.
- First-Line Dapagliflozin, Metformin, or Combination Therapy in Type 2 Diabetes: Vascular and Molecular Outcomes of a Randomised Controlled Trial.Diabetes, obesity & metabolism · 2026Trial
- Cellular and molecular mechanisms of thrombosis and thrombus-targeted thrombolytic strategies.Materials today. Bio · 2025Review
- Acute pulmonary embolism: a paradigm shift in interventional treatment and interdisciplinary care?European radiology · 2025Review
- Epitope mapping strategies for immunogenicity mitigation in streptokinase therapeutics: an in-silico study.Scientific reports · 2025Article
- Biomedical and environmental applications via nanobiocatalysts and enzyme immobilization.European journal of medical research · 2025Review
- Multivalent Tranexamic Acid (TXA) and Benzamidine Derivatives for Serine Protease Inhibition.ACS pharmacology & translational science · 2025Article
- Production of a Recombinant Fibrinolytic Protease from an Isolate of Serratia marcescens from the Amazon Basin.ACS omega · 2025Article
- Thrombolysis for acute ischaemic stroke: development and update.Brain communications · 2025Review
- Advances in Nano-Functional Materials in Targeted Thrombolytic Drug Delivery.Molecules (Basel, Switzerland) · 2024Review
- Review
- The effect of plasmin-mediated degradation on fibrinolysis and tissue plasminogen activator diffusion.Biophysical journal · 2024Article
- Article
- In Silico Study of Different Thrombolytic Agents for Fibrinolysis in Acute Ischemic Stroke.Pharmaceutics · 2023Article
- Population Pharmacokinetics of Tenecteplase in Patients With Acute Myocardial Infarction and Application to Patients With Acute Ischemic Stroke.Journal of clinical pharmacology · 2023Article
- Insights Into The Effects of Amino Acid Substitutions on The Stability of Reteplase Structure: A Molecular Dynamics Simulation Study.Iranian journal of biotechnology · 2023Article
- A Brief Review of Thrombolytics for Venous Interventions.Seminars in interventional radiology · 2022Review
- 2022 Update of the Consensus on the Rational Use of Antithrombotics and Thrombolytics in Veterinary Critical Care (CURATIVE) Domain 6: Defining rational use of thrombolytics.Journal of veterinary emergency and critical care (San Antonio, Tex. : 2001) · 2022Article
- Rational design of a new variant of Reteplase with optimized physicochemical profile and large-scale production in Escherichia coli.World journal of microbiology & biotechnology · 2022Article
- Study on the activity of recombinant mutant tissue-type plasminogen activator fused with the C-terminal fragment of hirudin.Journal of thrombosis and thrombolysis · 2021Article
- Thrombolytic Enzymes of Microbial Origin: A Review.International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular disorders are on the rise worldwide due to alcohol abuse, obesity, hypertension, raised blood lipids, diabetes and age-related risks. The use of classical antiplatelet and anticoagulant therapies combined with surgical intervention helped to clear blood clots during the inceptive years. However, the discovery of streptokinase and urokinase ushered the way of using these enzymes as thrombolytic agents to degrade the fibrin network with an issue of systemic hemorrhage. The development of second generation plasminogen activators like anistreplase and tissue plasminogen activator partially controlled this problem. The third generation molecules, majorly t-PA variants, showed desirable properties of improved stability, safety and efficacy with enhanced fibrin specificity. Plasmin variants are produced as direct fibrinolytic agents as a futuristic approach with targeted delivery of these drugs using liposome technlogy. The novel molecules from microbial, plant and animal origin present the future of direct thrombolytics due to their safety and ease of administration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.